Highlights Eton Pharmaceuticals, Inc.

Equities

ETON

US29772L1089

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
3.43 ^USD	-0.15%		-7.55%	-21.69%

05-09	Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q1 Revenue $8M, vs. Street Est of $8M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q1 Revenue $8M, vs. Street Est of $8M	05-09	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	04-30	MT
Eton Pharmaceuticals Submits New Drug Application to FDA For ET-400	04-30	MT
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)	04-30	CI
Sector Update: Health Care Stocks Steady Pre-Bell Friday	03-22	MT
Sector Update: Health Care	03-22	MT
Eton Pharmaceuticals Acquires U.S. Rights to PKU GOLIKE from Relief Therapeutics Holding SA	03-22	CI
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product	03-22	MT
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike	03-22	MT
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q4 Revenue $7.3M, vs. Street Est of $7.66M	03-14	MT
Eton Pharmaceuticals' ET-400 Protect Candidate Approved for US Patent	02-21	MT
Eton Pharmaceuticals Awards U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation	02-21	CI
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules	02-02	CI
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q3 Revenue $7M, vs. Street Est of $6.3M	11-09	MT
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone	04/10/23	CI
Eton Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023	10/08/23	CI
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q2 Revenue $12M, vs. Street Est of $6.5M	10/08/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Eton Pharmaceuticals, Inc.

Equities

ETON

US29772L1089

Highlights

Filters